Evidence map›Paper›PMID 25006189›Full record

ReviewJournal of the National Cancer Institute2014

Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials.

Bhishamjit S Chera, Avraham Eisbruch, Barbara A Murphy, John A Ridge, Patrick Gavin, Bryce B Reeve, Deborah Watkins Bruner, Benjamin Movsas

Abstract readConsensus Development Conference, NIHReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the National Cancer Institute, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  5. Confounding factors associated with oral mucositis assessment in patients receiving chemoradiotherapy for head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017
    Trial
  6. Trial
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Bhishamjit S CheraAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM). bchera@med.unc.edu.
Avraham EisbruchAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
Barbara A MurphyAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
John A RidgeAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
Patrick GavinAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
Bryce B ReeveAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
Deborah Watkins BrunerAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).
Benjamin MovsasAffiliations of authors: Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC (BSC, BBR); Department of Radiation Oncology, University of Michigan, Ann Arbor, MI (AE); Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN (BAM); Fox Chase Cancer Center, Philadelphia, PA (JAR); Grand Rapids Clinical Oncology Program, Grand Rapids, MI (PG); Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA (DWB); Henry Ford Hospital, Detroit, MI (BM).

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

We identified a standard core set of patient-reported symptoms and health-related quality-of-life (HRQOL) domains to be assessed in head and neck (H&N) cancer clinical trials. The core symptom and HRQOL domain scores were used to guide recommendations by a working group of experts as part of a National Cancer Institute Symptom Management and HRQOL Clinical Trials Planning Meeting. A PubMed search was conducted using the search terms of "health-related quality of life" and "head & neck cancer," limited to publications from January 1, 2000, to December 31, 2010. Fifty-four articles were used to guide the choice of recommendations. Twenty-nine symptoms and nine domains were identified, from which 12 H&N-specific core symptoms and HRQOL domains were recommended: swallowing, oral pain, skin changes, dry mouth, dental health, opening mouth/trismus, taste, excess/thick mucous/saliva, shoulder disability/motion, voice/hoarseness, social domain, and functional domain. This core set of 12 H&N-specific, patient-reported symptoms and HRQOL domains should be assessed in future H&N cancer clinical trials.

Indexed as

Quality of LifeSelf ReportClinical Trials as TopicDeglutition DisordersFacial PainHead and Neck NeoplasmsHealth StatusHoarsenessHumansNational Cancer Institute (U.S.)SialorrheaSurveys and QuestionnairesTreatment OutcomeTrismusUnited StatesXerostomia

Identifiers

PMID25006189
PMCPMC4192043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.